Organisation paid for research Program year 2025 Source: CMS Open Payments

Metroplex Pulmonary and Sleep Center

Neither a doctor nor a teaching hospital

Research payments

$5,613,882

1,340 payments

Through program year 2025, Metroplex Pulmonary and Sleep Center is reported as receiving $5,613,882 in research payments, across 1,340 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,866,783 236
2024 Research $1,520,099 852
2023 Research $727,774 74
2022 Research $491,267 61
2021 Research $275,190 19
2020 Research $199,125 19
2019 Research $533,644 79

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $1,574,463 115 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $607,524 15 payments
  3. Genzyme Corporation $469,880 51 payments
  4. Genentech, Inc. $446,102 50 payments
  5. Amgen Inc. $445,827 4 payments
  6. Chiesi USA, Inc. $365,514 46 payments
  7. Teva Pharmaceuticals USA, Inc. $354,086 64 payments
  8. Hikma Pharmaceuticals USA $315,210 9 payments
  9. United Therapeutics Corporation $293,302 68 payments
  10. Roche Products Limited $248,962 33 payments
Studies the money was for Research payments · program years 2019–2025
  1. CatC inhibitor Phase II in bronchiectasis $492,468 7 payments
  2. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $452,880 50 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $447,427 15 payments
  4. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $327,412 28 payments
  5. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma $318,312 1 payment
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $232,093 21 payments
  7. Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $223,560 27 payments
  8. PH Iib of Astegolimab in COPD $204,094 15 payments
  9. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $198,668 35 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis $185,555 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record